The document discusses the potential for a telemedicine pilot program to serve patients with rare diseases. It summarizes surveys that found over 50% of patients would be receptive to telemedicine and over 90% are willing to learn video call applications. The document estimates a 3-year pilot program could save £6.8 million in healthcare costs while costing approximately £975,000 to implement. Key operational requirements for the pilot include videoconferencing capabilities and secure data protection.
In this webinar, our panelists explored ethics, transparency, resources, alignment and conflicts in the important relationships between companies and patient groups.
This webinar presented perspectives from subject matter experts from the innovative medicines industry, governance experts, and patient advocates.
Panelists:
Hugh Scott, Executive Director, Strategic Alliances at Innovative Medicines Canada.
Rosy Sasso, acting Director, Ethics and Compliance at Innovative Medicines Canada.
Brian Huskins, the Senior Fellow of Not-For-Profit Governance at the Institute on Governance.
Martine Elias, Director of Access, Advocacy & Community Relations with Myeloma Canada.
Dr. Durhane Wong-Rieger, PhD, President and CEO of the Canadian Organization for Rare Disorders.
Moderator: Bill Dempster, 3Sixty Public Affairs
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Discussion of the CADTH Symposium
● Recommendations for HTA improvements in Canada
● Audience Q&A
View the video: https://youtu.be/AJCOemf2r6Y
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Patient Centricity in Pharmacovigilance: New Directions and New Horizons for ...Covance
The importance of pharmacovigilance (PV) as a science, critical to both effective patient care in clinical practice and public health is growing. **Disclaimer: This article was previously published. Sciformix is now a Covance company.
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on the Canadian public and private drug access environment
● A moderated panel on the broader access and innovation context, featuring an update on international access to innovative therapies, patient support programs, and innovative pathways for access to treatments
View the video:
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
The Canadian Cancer Survivor Network (CCSN) conducted a survey in April 2013 the discover the impact that being involved in volunteer advocacy and/or the development of public policy has on cancer patients, survivors, caregivers and family members. 51 people completed the survey. Findings were that patient advocacy generally has a positive impact on the self-image of those doing it, that many volunteer advocates felt better, prouder, more useful, more hopeful, more effective and more powerful. Still others felt less angry, less anxious, and less sad. But some survey respondents did feel sadder, angrier, less hopeful and less content. CCSN recommends that organizations ensure that cancer patients involved in advocacy activities receive skills to help them and support to deal with the often slow-moving and sometimes frustrating healthcare, cancer care and government systems in Canada.
In this webinar, our panelists explored ethics, transparency, resources, alignment and conflicts in the important relationships between companies and patient groups.
This webinar presented perspectives from subject matter experts from the innovative medicines industry, governance experts, and patient advocates.
Panelists:
Hugh Scott, Executive Director, Strategic Alliances at Innovative Medicines Canada.
Rosy Sasso, acting Director, Ethics and Compliance at Innovative Medicines Canada.
Brian Huskins, the Senior Fellow of Not-For-Profit Governance at the Institute on Governance.
Martine Elias, Director of Access, Advocacy & Community Relations with Myeloma Canada.
Dr. Durhane Wong-Rieger, PhD, President and CEO of the Canadian Organization for Rare Disorders.
Moderator: Bill Dempster, 3Sixty Public Affairs
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Discussion of the CADTH Symposium
● Recommendations for HTA improvements in Canada
● Audience Q&A
View the video: https://youtu.be/AJCOemf2r6Y
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Patient Centricity in Pharmacovigilance: New Directions and New Horizons for ...Covance
The importance of pharmacovigilance (PV) as a science, critical to both effective patient care in clinical practice and public health is growing. **Disclaimer: This article was previously published. Sciformix is now a Covance company.
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on the Canadian public and private drug access environment
● A moderated panel on the broader access and innovation context, featuring an update on international access to innovative therapies, patient support programs, and innovative pathways for access to treatments
View the video:
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
The Canadian Cancer Survivor Network (CCSN) conducted a survey in April 2013 the discover the impact that being involved in volunteer advocacy and/or the development of public policy has on cancer patients, survivors, caregivers and family members. 51 people completed the survey. Findings were that patient advocacy generally has a positive impact on the self-image of those doing it, that many volunteer advocates felt better, prouder, more useful, more hopeful, more effective and more powerful. Still others felt less angry, less anxious, and less sad. But some survey respondents did feel sadder, angrier, less hopeful and less content. CCSN recommends that organizations ensure that cancer patients involved in advocacy activities receive skills to help them and support to deal with the often slow-moving and sometimes frustrating healthcare, cancer care and government systems in Canada.
Is there patient involvement in HTA? Can patients influence HTA decision making?Kathi Apostolidis
Is HTA purely technical?
drivers for patient involvement in HTA
patient participation or tokenism
medicines do not reach patients due to delays in HTA evaluation
need for harmonized HTA
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...Nathan White, CPC
The recent enactment of the 21st Century Cures Act has profound immediate and long-term implications for development and communication of HEOR/RWE in the US, particularly in relation to communications with payors about healthcare economic information (HCEI). In January, the FDA released draft guidance for public comment to outline its thinking around communication to payors of HCEI, but there are still unanswered questions to be addressed in the final guidance. Industry will need to quickly establish new policies and procedures to maintain compliance with the new regulations, especially in relation to OPDP submission requirements – a steep transition from a space that has largely been unregulated.
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Takeaways from a roundtable held on June 1st about patient-centred pharmacare in Canada
● Reports from patient groups and other subject matter experts
● A cohesive vision and set of values for national pharmacare in Canada
View the video: https://youtu.be/HMy_gsTDkfI
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Presentation done at CBEB'16 the 17th October by Vicente Traver introducing EIP-AHA and H2020 policies, the LINK project and different opportunities to cooperate together between Brazil and EU about telehealth and personal health
Amplifying the High-Touch of Specialty Pharmacy through Mobile and Web-Based ...Avella Specialty Pharmacy
Amplifying the High-Touch of Specialty Pharmacy through Mobile and Web-Based Tools. Learn more about medication adherence and mobile health tools from Avella Specialty Pharmacy: http://www.avella.com/medication-adherence
Is there patient involvement in HTA? Can patients influence HTA decision making?Kathi Apostolidis
Is HTA purely technical?
drivers for patient involvement in HTA
patient participation or tokenism
medicines do not reach patients due to delays in HTA evaluation
need for harmonized HTA
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...Nathan White, CPC
The recent enactment of the 21st Century Cures Act has profound immediate and long-term implications for development and communication of HEOR/RWE in the US, particularly in relation to communications with payors about healthcare economic information (HCEI). In January, the FDA released draft guidance for public comment to outline its thinking around communication to payors of HCEI, but there are still unanswered questions to be addressed in the final guidance. Industry will need to quickly establish new policies and procedures to maintain compliance with the new regulations, especially in relation to OPDP submission requirements – a steep transition from a space that has largely been unregulated.
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Takeaways from a roundtable held on June 1st about patient-centred pharmacare in Canada
● Reports from patient groups and other subject matter experts
● A cohesive vision and set of values for national pharmacare in Canada
View the video: https://youtu.be/HMy_gsTDkfI
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Presentation done at CBEB'16 the 17th October by Vicente Traver introducing EIP-AHA and H2020 policies, the LINK project and different opportunities to cooperate together between Brazil and EU about telehealth and personal health
Amplifying the High-Touch of Specialty Pharmacy through Mobile and Web-Based ...Avella Specialty Pharmacy
Amplifying the High-Touch of Specialty Pharmacy through Mobile and Web-Based Tools. Learn more about medication adherence and mobile health tools from Avella Specialty Pharmacy: http://www.avella.com/medication-adherence
eHealth as a tool to support health practitioners November 2013Rajeev Rao Eashwari
“Telemedicine begins with a vision of connecting people to people, connecting resources to needs, and connecting healthcare problems to health care solutions”
Telecommunication systems applied to telemedicineShazia Iqbal
Telemedicine allows health care professionals to evaluate, diagnose and treat patients at a distance using telecommunications technology.
The approach has been through a striking evolution in the last decade and it is becoming an increasingly important.
Process Automation in Telemedicine - The Italian PerspectiveDenis Gagné
Presented by Baxter, with the participation of Telemedicine Observatory by ALTEMS (Università Cattolica del Sacro Cuore, Rome).
Stefano Collatina, Country Head Baxter Italy
Prof. Fabrizio Ferrara, Universita Cattolica del Sacro Cuore
Simone Naso, Digital Health Specialist, Baxter Italy
Health care delivery in Italy represents a number of challenges, including the regulatory requirements and the regional differences. Telemedicine has the potential to provide more cost-effective care, especially for vulnerable populations such as the elderly. In this webinar the unique needs of Italy will be discussed and how they can be addressed by standards-based process automation.
Healthcare delivery continues to evolve and change as new technology and regulations come to light. Telehealth has come to the forefront as the new paradigm for healthcare in many clinical situations.
In this session, IVCi and Avizia reveal the:
Best practices for adoption of telemedicine.
Expansion of telemedicine into new service lines & trends of innovation.
Many uses of telemedicine for prevention based applications.
Heavily based on a presentation I gave for the CMS 2020 National Quality Forum. Emphasis is on dialysis (particularly home dialysis). Discusses regulatory framework, medical devices used to render the services and outcomes of studies performed to day
A Trust-Centric Healthcare Journey Part II | Full Presentation of PharmaLedge...PharmaLedger
In this presentation, you will find:
An introduction to the PharmaLedger project presented by Maria Eugenia (Xenia) Beltran | Project Coordinator / DRA and Use Case co-lead (Universidad Politécnica de Madrid)
Topic 1 | Clinical Trial eRecruitment | Despina Daliani (Onorach) and Ken Nessel (Pfizer)
Topic 2 | Clinical Trial eConsent | Hernando C. Giraldo (Boehringer Ingelheim) and Despina Daliani (Onorach)
Topic 3 | Health Data IoT Medical Device | Disa Lee Choun (UCB) and Francesca Rocchi (Bambino Gesù Children Hospital)
Topic 4 | Health Data Personalised Medicine | Beatriz Merino (Universidad Politécnica de Madrid) and Christos Kontogiorgis (Democritus University of Thrace)
You can also learn more about our #2 Open Webinar on Clinical Trials & Health Data by rewatching our video recording including the Q&A by clicking on the button below:
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
At CamRARE's RAREsummit23 on 12 Oct, Chair of the Trustees, Dr Gemma Chandratillake, presented a visual slideshow of CamRARE's highlights, achievements and impact since our last in person RAREsummit in 2019.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
3. 1 Demand for a telemedicine pilot program
Operational requirements of a telemedicine pilot
Cost of a potential telemedicine pilot program3
4 Rare Disease Nurse Network
1
Content
2
3
4. Executive Summary
● There is strong demand for a telemedicine pilot program from rare
disease patients. Our survey findings indicates that a majority of patients
are receptive to a telemedicine pilot -- over 50% believe telemedicine will
help them save money and time, while improving quality of care received.
Over 90% of patients are willing to learn how to use video call applications.
● We identified four potential telemedicine models and key operational
requirements. We recommend having Case Managers to act as a single
point of contact for patients. Necessary infrastructure for the pilot should
include (i) video conferencing capabilities and (ii) secure data protection.
● A 3-year telemedicine pilot program is estimated to bring at least
£6.8M in healthcare cost savings while the project itself will cost
approx. £975k. There is further scope for cost containment through
outsourcing or using cloud storage.
4
5. The project is structured into four phases,
each containing separate work streams
5
Phase 1
Background research
Phase 2
Establishing
feasibility of
telemedicine pilot
Phase 3
In-depth cost
analysis
Phase 4
Preparing for
consortium bid
• Examine already
established
international
pilots
• Interview KOLs to
understand the
benefits of, and
need for,
telemedicine
• Establish demand
for telemedicine
pilot by creating
and conducting
surveys
• Talk to leaders of
existing services
• Obtain hospital
administration
feedback on how
telemedicine might
affect care
• Develop
infrastructural
model
• Perform in-depth
cost analysis
based on current
models
• Leverage insights
from Phases 1/2 to
develop a cost
model
• Categorise
different funding
sources
• Seek partners
within the CRDN
network
• Ensure participants
develop impact of
pilot together
• Develop an
implementation
plan for launching
pilot study and
scaling up
(UK-wide)
6. Collectively, rare diseases are not ‘rare’, both
nationally in the UK and regionally in Cambridge
Source: Previous CCN analysis
6
Nationally, there are ~3 million
patients with rare diseases
• A rare disease is a life-threatening or
chronic disease that affects less than
5 people in 10,000
• 1 in 17 people will suffer from a rare
disease
• UK population in 2016 was
~65 million
• In Cambridgeshire, the population is
~800,000
At least 3,000 patients reside in
Cambridge
7. Rare disease patients are confronted with a range
of challenges
7
Source: RareReality 2016
http://www.raredisease.org.uk/our-work/the-rare-reality-an-insight-into-the-patient-and-family-experience-of-rare-disease-2016/
8. Telemedicine would impact multiple stakeholders
Patients Hospitals
Families
Healthcare
professionals
Telemedicine affects every facet of the
healthcare system
8
9. Telemedicine has the potential to generate tangible
benefits for the entire healthcare system
Source: Widespread deployment of telemedicine services in Europe
ec.europa.eu/information_society/newsroom/cf/dae/document.cfm?doc_id=5167
● Provide access to
scarce expertise
● Reduce delays in
correct diagnosis
● Reduce travel costs
and save time
Telemedicine has the power to improve the patient experience significantly
9
Patients Doctors Hospitals
● Provide access to
scarce expertise
● Reduce delays in
correct diagnosis
● Reduce travel costs and
save time
● Reduce absenteeism
and late appointments
● Upskill doctors in
patient’s local area
● Provide holistic patient
care by interacting with
other specialists
● Generate cost savings
● Access to patients to
conduct clinical research
10. Successful telemedicine pilots in paediatric care in
Queensland, Australia provide award-winning care
The Centre for Online Health has pioneered a
unique way to deal with Queensland’s rural
population
90% of referrals lead
to consultations via
video conference
Over 15,000
consultations have
been conducted
since 2000
37 different
subspecialties of
paediatric care are
offered
Significant savings
for the healthcare
provider and
patients were
generated
Source: University of Queensland. https://www.uq.edu.au/news/article/2011/09/award-winning-telemedicine-trial-sick-infants
10
11. Scotland has adopted telemedicine programmes
more quickly than other countries
Source: Scottish Centre for Telehealth and Telecare 2016 Report https://sctt.org.uk/sctt-end-year-report/
11
Scottish Centre of
Telehealth & Telecare
Partners
Mastermind is a
computerised cognitive
behaviour therapy for
patients suffering from
mental health problems
United4Health is a
telemonitoring service for
patients with Diabetes,
COPD and Congestive Heart
Failure
SmartCare is in development
to deliver better
coordination and integrated
care with 7 health and care
partnerships
Living It Up is an online
supported,
self-management service for
people with long term health
and care conditions
12. Survey establishes patient’s demand for a
telemedicine pilot programme
Aims of survey
Determine rare disease
patient preferences and
support for telemedicine
vs
in-person visits
Determine if patients
can easily access a
telemedicine platform to
participate in pilot
12
• Main groups of patients targeted are seen at Addenbrooke’s Lysosomal Disorder Unit (250
patients), Addenbrooke's Severe Insulin Resistance Clinic (150 patients) and Birmingham
Children’s Hospital
(280 patients)
• Disseminated to patients via CRDN and other platforms
Patients
targeted
• Examine the proportion of patients choosing different answers across each questions using pie
charts and bar graphs
• Compare the different segments of patients, based on age of patient and the clinic the patient is
seen at
Methods of
analysis
13. Percentage of respondents who are willing to
participate in a telemedicine pilot
● Number of respondents: 67
● 60% willing to participate in telemedicine trial (pilot)
13
16. Necessary components of the pilot pose potential
challenges for setup
Essential
factors for the
pilot
Operational requirements
Legal requirements
16
17. Proposal:
Regional
Case
Managers
One-stop
shop
service
Single point of
contact for advice,
care and support
PILOT
Centre:
NoRo Centre,
Romania
Target
population:
Patients with
rare diseases
Cases per
manager:
30 (simultaneous)
Time frame:
18 months
(Jan 17–Jun 18)
EURORDIS: European Organisation for Rare Diseases
Source: Interview with Raquel Castro
17
EURORDIS’s InnovCare Project provided insight into
designing a pilot study in Romania
18. Source: Interview with Raquel Castro
18
The InnovCare project focuses on the role of case managers
as a single point of contact for all patient needs
• Single and stable point of contact: hub of information and knowledge
• Listen, inform, support and empower patients and families, as well as
professionals involved in
care provision
• Facilitating coordination between services and networks of service providers
• Assessment/monitoring of needs, and observing those needs
Role of case
managers
• Centre has existing provisions: physical therapy, speech therapy, training for staff,
information and guidance services, etc.
• Romanian healthcare system has a centralised software for patient files
and data
Existing
infrastructure
19. Challenges
Administrative
Case Managers considered
“threatening” and
interfering by care
providers -
Important to introduce in
an appropriate way
19
Challenges faced while setting up the Romanian pilot were
centred on obtaining robust technology
Technological
Limited/compromised access
to internet, and insufficient
connection for
teleconferences
Need at least one person to
fix these problems
20. OrangeHealth – setting up telemedicine projects in France (three regions)
20
Source: Interview with Andrew Green (OrangeHealth)
Telemedicine pilot set up in France suggests companies for
workflow software and teleconferencing software
Infrastructure
● Workflow management
● Cloud-based patient file management
● Access to patient data
● Imaging systems
● Equipment: camera, screens, network connections
Acceois provided the software for telemedicine workflow management
Equatel provided robust teleconference terminals – links with monitoring equipment
21. Operational requirements will require expansion of
current infrastructure
Operational
requirements for
telemedicine pilot
Working infrastructure:
working computers/tablets
with cameras
Seminar rooms/space for calls
Internet connection
Robust and secure: patient
and specialist
e-Health records
Constant access to the
patients files
Reliable teleconference
software
complies with privacy
regulations around
access to records
Source: CCN interviews with key opinion leaders and Scotland pilot program
21
22. Legal infrastructure for Romanian pilot was governed
by national regulations
Data protection
and legal
infrastructure
The NoRo centre has social service and healthcare
provider status
Source: Interview with Raquel Castro
Patient files are under the control of the patient:
patient decides, patient shares
22
23. Telemedicine pilot set up in France by OrangeHealth
focused on the efforts made to comply with data privacy
Source: Interview with Andrew Green (OrangeHealth)
23
Data protection
● OrangeHealth provided virtual private network (VPN)
● OrangeCloud hosted data
Took 2 years to get approval
Issues:
● Full-time doctor availability
● Data duplication/back-up
● Data vulnerability
● Intrusion by external forces
Both comply with
France’s regulations
24. Both hospitals being considered for the pilot have
governance teams for ensuring data protection
Birmingham Children’s Hospital
Own Information Governance team,
that complies with national data
privacy regulations
Addenbrooke’s Hospital
Own Information Governance team,
ensuring that patient information is
dealt with legally and securely to
appropriate ethical and quality
standards (10 standards and
requirements, including Health Records
Management, Confidentiality and the
Data Protection Act 1998)
24
25. Impact of data protection and operational requirements
on plans for telemedicine arrangements
DATA PROTECTION
Informed consent of pilot
participants is important
● Main concern during group
calls with consultant
● Patients may be uncomfortable
with exposure to private data
OPERATIONAL REQUIREMENTS
Direct impact on all
arrangements
● Equipment with camera
is crucial
● E-health records must be
available to the doctor in order
to make best medical decisions
25
26. Telemedicine
arrangement formats
(via video calls)
Patient to specialist
nurse/physician
from patient’s home
Small groups of patients
to specialist doctor
Patient at local GP to
specialist nurse/physician
Patient to specialist
nurse/physician + remote
monitoring of
physiological parameters
Proposed telemedicine arrangements have been
narrowed down to four potential formats
Source: CCN interviews with key opinion leaders
26
27. Patient at local GP to specialist nurse/physician model
may not get the GP buy-in necessary for success
Source: Interview with Helena Baker (Medical Research Network)
27
1. GP workload prohibits taking on additional responsibility
“The key issue with that model is you don’t get GP buy-in. The GPs are under such huge
pressure, and when a patient has a rare disease, GPs very much want the consultants
to come in and deal with that.”
2. Lack of education buy-in among GPs
“There is a small cohort of GPs interested in continuing education and doing exciting
new novel things like that – the vast majority won’t. But only 5% of GPs take part in
clinical trials anyway.”
3. Logistical difficulty in lining up schedules
Both GPs and consultants already sometimes face issues with scheduling, as clinics they
have with patients sometimes start late. This will pose a significant challenge should
both parties be involved in a given consultation.
28. A 3-year telemedicine pilot programme in Cambridgeshire is
likely to save £34 million by improving healthcare outcomes
Source: WDS Headline Findings & The King’s Fund Publications.
https://www.kingsfund.org.uk/publications/articles/kent-telehealth-pilot-study
28
Case study in Kent
• As indicated in the
pilot study, telemedicine
could reduce clinician
home visits, unplanned
admissions and
A&E visits
• The 6-month pilot study
has led to an average
saving of £1,878 per
patient
Extrapolating to Cambridgeshire
• A 3-year pilot programme in
Cambridgeshire is therefore likely to
save £1,878 x 6 = £11,268 per patient
• Assuming 3,000 patients with rare
diseases live in Cambridgeshire, the
aggregate saving would be £34 million,
plus improved health care outcomes
• These figures further highlight
the effectiveness of telemedicine
in cost-savings
29. Cost difference for each telemedicine meeting vs. in-person visit
• Assume average travel costs around Cambridgeshire is £20
for a round trip
• Assume each visit consumes 1 hour on the road and costs
£44 for nurse hourly wage (not directly patient-related work)
Compared to in-person visits by nurses, the use of a
telemedicine platform could further save £44 costs per meeting
Source: Unit Costs of Health and Social Care 2015; http://www.pssru.ac.uk/project-pages/unit-costs/2015/
Saving on
travel-related costs:
£64
Extra cost for
telemedicine platform:
£20
Each telemedicine meeting could save £64 - £20 = £44
• Market research indicates that telemedicine platforms (e.g. 1
Doc Way in the U.S.) cost c.£20/hour
• Assume each telemedicine meeting lasts at most 1 hour
29
30. 30
To construct a cost model for the pilot program, patient
segmentation is performed on Addenbrooke’s and BCH, followed
by fixed and variable cost projection
Variable
costs
Fixed
costs
Equipment
Overhead: Admin & IT staff
Training
Attributable nurse salary
Additional data storage
System maintenance and upgrade
Installation
Travel (reserve level)
Addenbrooke's Hospital (N=650)
● Lysosomal/Metabolic Disorder Unit (500)
● Severe Insulin Resistance Unit (150)
Birmingham Children’s Hospital (N=280)
● Autosomal Recessive Polycystic Kidney
Diseases (80)
● Cystic Fibrosis (100)
● Tumour Suppressor Complex (100)
Key assumptions
● UK internet access rate: 92%
● Initial adoption rate: 70%
● Annual dropout rate: 5%
● Additional buffer time for system handling: 15%
● Patient terminal: £405
● Hospital terminal: £6,098
Source: World Bank, Frost & Sullivan, Unit Costs of Health and Social Care 2013 & 2015; http://www.pssru.ac.uk/project-pages/unit-costs/2015/
31. Total cost of the 3-year pilot program is estimated at £975K, with
equipment costs and specialist nurse salaries being major cost drivers,
contributing to 31% and 28% of total cost, respectively
% of
total
31% 3% 4% 21% 28% 5% 5% 3% 100%
• Given the high requirement of upfront infrastructure investment, fixed costs account for 59% of total costs
• This further supports the idea of leveraging existing hardware resources, or procuring less customized
telemedicine solutions as long as the healthcare effectiveness is not compromised
31
32. Splitting costs along a timeline, initial setup costs take up 36% of
total costs, with the remaining costs evenly distributed throughout the
3-year pilot program period
• 61% of fixed costs will be incurred in the initial setup phase
• This indicates the possibility to achieve greater economies of scale (i.e. lower costs on a per
meeting basis) when the pilot program is extended to a longer period
• CRDN may opt for applying to additional grants or forming partnerships to finance a longer
program
32
33. For cost containment, besides equipment procurement, overhead and data
storage costs could further be reduced if IT and admin staff are outsourced
and cloud storage is used
Cost model summary for the 3-year telemedicine pilot program:
Source (model assumptions): World Bank, Office for National Statistics, Orange Health, Cambridge Consultants, Unit Costs of Health and Social Care
2013 & 2015; http://www.pssru.ac.uk/project-pages/unit-costs/2015/
33
34. Potential benefits of the pilot program is projected to be £6.8M
The telemedicine pilot program is estimated to bring 6.0x return on
investments and thus represents strong financial saving potential
• Extrapolating the cost-saving experience from Kent, a 3-year pilot study could lead to
an average financial saving of £11,268 per patient
• In the cost model, there would be 604 patients on average using the telemedicine
platform throughout the program horizon
• Therefore, the estimated benefits could amount to £11,268 X 604 =£6.80M
34
Estimated ROI = (£6.80M - £0.98M)/£0.98M = 6.0x
35. Cost difference for each telemedicine meeting vs. in-person visit
• Assume average travel costs around Cambridgeshire is £20
for a round trip
• Assume each visit consumes 1 hour on the road and costs
£44 for nurse hourly wage (not directly patient-related work)
Compared to in-person visits by nurses, the use of a
telemedicine platform could further save £44 costs per meeting
Source: Unit Costs of Health and Social Care 2015; http://www.pssru.ac.uk/project-pages/unit-costs/2015/
Saving on
travel-related costs:
£64
Extra cost for
telemedicine platform:
£20
Each telemedicine meeting could save £64 - £20 = £44
• Market research indicates that telemedicine platforms (e.g. 1
Doc Way in the U.S.) cost c.£20/hour
• Assume each telemedicine meeting lasts at most 1 hour
35
36. Executive Summary
● There is strong demand for a telemedicine pilot program from rare
disease patients. Our survey findings indicates that a majority of patients
are receptive to a telemedicine pilot -- over 50% believe telemedicine will
help them save money and time, while improving quality of care received.
Over 90% of patients are willing to learn how to use video call applications.
● We identified four potential telemedicine models and key operational
requirements. We recommend having Case Managers to act as a single
point of contact for patients. Necessary infrastructure for the pilot should
include (i) video conferencing capabilities and (ii) secure data protection.
● A 3-year telemedicine pilot program is estimated to bring at least
£6.8M in healthcare cost savings while the project itself will cost
approx. £975k. There is further scope for cost containment through
outsourcing or using cloud storage.
36
37. ‘This work has been undertaken as part of a student educational project and the material should be
viewed in this context. The work does not constitute professional advice and no warranties are made
regarding the information presented. Cambridge Consulting Network do not accept any liability for the
consequences of any action taken as a result of the work or any recommendations made or inferred’
Thank you
Natalie Rebeyev: nr406am.ac.uk
Saakshi Chadha: sc885@cam.ac.uk
37